Search research articles
Contact Us
Filters
Showing results (141-150 of 205) with videos related to
Page
of 21
Sort By:
Der Urologe. Ausg. A
|
October 27, 2017
[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data]
J E Gschwend, P Albers, M Bögemann, et al.
European Radiology
|
July 9, 2017
Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate
T Ullrich, M Quentin, A K Schmaltz, et al.
Urologia Internationalis
|
June 9, 2012
Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance
M Quentin, D Blondin, J Klasen, et al.
Onkologie
|
March 15, 2002
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life
P Albers, R Siener, M Härtlein, et al.
World Journal of Urology
|
January 1, 1994
Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection
P Albers, W deRiese, E B Walker, et al.
European Journal of Radiology
|
September 18, 2022
Impact of dynamic contrast-enhanced MRI in 1.5 T versus 3 T MRI for clinically significant prostate cancer detection
F Ziayee, L Schimmöller, D Blondin, et al.
European Radiology
|
June 28, 2020
Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study
T Ullrich, C Arsov, M Quentin, et al.
International Journal of Cancer
|
December 22, 1999
Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group
P Albers, R Siener, M Hartmann, et al.
Urology
|
February 25, 2003
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells
G Fechner, F G E Perabo, D H Schmidt, et al.
Der Urologe. Ausg. A
|
July 12, 2017
[Metastatic prostate cancer : Update: position paper for the use of chemotherapy]
C-H Ohlmann, P J Goebell, M-O Grimm, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 205) with videos related to
Sort By:
Page
of 21
Der Urologe. Ausg. A
|
October 27, 2017
[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data]
J E Gschwend, P Albers, M Bögemann, et al.
European Radiology
|
July 9, 2017
Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate
T Ullrich, M Quentin, A K Schmaltz, et al.
Urologia Internationalis
|
June 9, 2012
Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance
M Quentin, D Blondin, J Klasen, et al.
Onkologie
|
March 15, 2002
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life
P Albers, R Siener, M Härtlein, et al.
World Journal of Urology
|
January 1, 1994
Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection
P Albers, W deRiese, E B Walker, et al.
European Journal of Radiology
|
September 18, 2022
Impact of dynamic contrast-enhanced MRI in 1.5 T versus 3 T MRI for clinically significant prostate cancer detection
F Ziayee, L Schimmöller, D Blondin, et al.
European Radiology
|
June 28, 2020
Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study
T Ullrich, C Arsov, M Quentin, et al.
International Journal of Cancer
|
December 22, 1999
Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group
P Albers, R Siener, M Hartmann, et al.
Urology
|
February 25, 2003
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells
G Fechner, F G E Perabo, D H Schmidt, et al.
Der Urologe. Ausg. A
|
July 12, 2017
[Metastatic prostate cancer : Update: position paper for the use of chemotherapy]
C-H Ohlmann, P J Goebell, M-O Grimm, et al.
Page
of 21